Everyone's Watching SpaceX -- but This IPO Stock Could Have Much Bigger Upside

Oura filed confidential IPO paperwork on May 21, 2026 and was valued at $11 billion in its October 2025 funding round, implying about 5.5x projected 2026 sales versus SpaceX's much richer valuation profile. The article highlights Oura's profitable hardware-plus-subscription model, with 2025 sales around $1 billion and potential to nearly double to $2 billion in 2026. Key risk is competition from Apple and Samsung in smart rings and wearables.

Analysis

Oura is the cleaner public-market expression of the wearables/consumer-health thesis: subscription-heavy, asset-light, and far easier to underwrite than a capital burner with long-dated execution risk. The first-order beneficiary is not Apple; it’s the entire cohort of digital-health and wearable component suppliers that can ride a broader re-rating of the category as investors rediscover recurring-revenue hardware.

The second-order issue is distribution, not product. If the IPO creates a valuation benchmark, the real winner is the company that can pair biometric data with an ecosystem moat; the real loser is the standalone device maker. That means Apple is the strategic overhang: even a modest smart-ring push would compress Oura’s terminal multiple far faster than headline unit growth would expand it, because the market will price the threat before it shows up in revenue.

The key contrarian point is that the IPO may be less about one company and more about category validation after a long drought in consumer-health listings. In the next 3-6 months, the stock could trade well if scarcity value and subscription optics dominate. Over 12-24 months, the risk is that investors realize the TAM is being shared with platform owners, and the multiple de-rates from “category leader” toward “feature with a brand” if engagement weakens or if Apple formalizes a competing roadmap.

Key Decisions for Investors

• Watchlist only into the IPO: avoid chasing day-1 strength; look to buy 2-4 weeks post-lockup/price discovery if the stock holds above the initial range and recurring revenue metrics confirm stability.
• Pair trade idea: long OURA if listed / short AAPL as a tactical hedge against competitive encroachment narrative; target 6-12 months, stop if Apple signals a ring product or acquires a competitor.
• Long AAPL downside hedged via call spread structure if you want to express competitive risk without outright equity short exposure; thesis horizon 3-9 months, especially ahead of product-cycle updates.
• Secondary beneficiaries: consider a basket long of wearable/health-data enablers (e.g., component and sensor suppliers) on any category re-rating; these names can benefit even if Oura-specific execution disappoints.
• If Oura trades at >8x forward sales without evidence of retention durability, fade via put spreads or a short after lockup expiration; the risk/reward improves once the market has to price in competition rather than narrative.